A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

This study aims to investigate the combination of BNT324, a B7-H3 antibody-drug conjugate (ADC) with BNT327, a programmed death-ligand 1 (PD-L1) and vascular endothelial growth factor (VEGF) bispecific antibody, in participants with advanced/metastatic or relapsed/progressive small cell lung cancer (SCLC) and non small cell lung cancer (NSCLC).

Trial Details

NCT ID
NCT06892548
Phase
PHASE1 / PHASE2
Sponsor
BioNTech SE
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • BNT324
  • BNT327
Locations (sample)
  • Phoenix, Arizona, United States|33.44838,-112.07404
  • Beverly Hills, California, United States|34.07362,-118.40036
  • Los Angeles, California, United States|34.05223,-118.24368
  • Santa Monica, California, United States|34.01949,-118.49138
  • Aurora, Colorado, United States|39.72943,-104.83192

Key Eligibility Criteria

  • Aged ≥18 years at the time of giving informed consent.
  • Histological or cytological confirmed unresectable advanced/metastatic lung cancer. Histological classification may be based on tumor samples prior…
  • Part 1: Participants with NSCLC and SCLC
  • Part 2 Cohort 1: Participants with NSCLC (subpopulation 1) AGA negative, 1L

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →